These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23160229)

  • 1. Natalizumab in the treatment of pediatric multiple sclerosis.
    Talab R; Talabova M; Klzo L
    Neuro Endocrinol Lett; 2012; 33(6):579-89. PubMed ID: 23160229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological markers of optimal response to natalizumab in multiple sclerosis.
    Villar LM; García-Sánchez MI; Costa-Frossard L; Espiño M; Roldán E; Páramo D; Lucas M; Izquierdo G; Álvarez-Cermeño JC
    Arch Neurol; 2012 Feb; 69(2):191-7. PubMed ID: 22332187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.
    Horga A; Castillo J; Rio J; Tintore M; Auger C; Sastre-Garriga J; Edo MC; Perez-Miralles F; Tur C; Nos C; Huerga E; Comabella M; Rovira A; Montalban X
    Rev Neurol; 2011 Mar; 52(6):321-30. PubMed ID: 21387248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab treatment in pediatric multiple sclerosis: a case report.
    Borriello G; Prosperini L; Luchetti A; Pozzilli C
    Eur J Paediatr Neurol; 2009 Jan; 13(1):67-71. PubMed ID: 18406645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab use in pediatric multiple sclerosis.
    Huppke P; Stark W; Zürcher C; Huppke B; Brück W; Gärtner J
    Arch Neurol; 2008 Dec; 65(12):1655-8. PubMed ID: 19064754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
    Vennegoor A; Rispens T; Strijbis EM; Seewann A; Uitdehaag BM; Balk LJ; Barkhof F; Polman CH; Wolbink G; Killestein J
    Mult Scler; 2013 Apr; 19(5):593-600. PubMed ID: 22992450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
    Yousry TA; Pelletier D; Cadavid D; Gass A; Richert ND; Radue EW; Filippi M
    Ann Neurol; 2012 Nov; 72(5):779-87. PubMed ID: 23280794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases.
    Hoevenaren IA; de Vries LC; Rijnders RJ; Lotgering FK
    Acta Neurol Scand; 2011 Jun; 123(6):430-3. PubMed ID: 21492099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients.
    Magraner M; Coret F; Casanova B
    Eur J Radiol; 2012 Nov; 81(11):3485-90. PubMed ID: 22391507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features of children and adolescents with multiple sclerosis.
    Ness JM; Chabas D; Sadovnick AD; Pohl D; Banwell B; Weinstock-Guttman B;
    Neurology; 2007 Apr; 68(16 Suppl 2):S37-45. PubMed ID: 17438237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis.
    Grimaldi LM; Prosperini L; Vitello G; Borriello G; Fubelli F; Pozzilli C
    Mult Scler; 2012 Sep; 18(9):1337-9. PubMed ID: 22389413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab use in patients with pediatric multiple sclerosis.
    Gorman MP; Tillema JM; Ciliax AM; Guttmann CR; Chitnis T
    Arch Neurol; 2012 Jan; 69(1):78-81. PubMed ID: 22232346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does natalizumab therapy worsen neuromyelitis optica?
    Jacob A; Hutchinson M; Elsone L; Kelly S; Ali R; Saukans I; Tubridy N; Boggild M
    Neurology; 2012 Sep; 79(10):1065-6. PubMed ID: 22914835
    [No Abstract]   [Full Text] [Related]  

  • 15. Latent tuberculosis seems not to reactivate in multiple sclerosis patients on natalizumab.
    Mulero P; Caminero AB; Neri Crespo MJ; Fernández-Herranz R; Téllez Lara N
    J Neuroimmunol; 2012 Feb; 243(1-2):103-5. PubMed ID: 22226471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rare case of no effective therapy with natalizumab (tisabri) in a female patient with multiple sclerosis and neutralizing antibodies to the drug].
    Iakushina TI; Eliseev IuV; Kotov SV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):83-6. PubMed ID: 23528600
    [No Abstract]   [Full Text] [Related]  

  • 18. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.
    Halpern R; Agarwal S; Borton L; Oneacre K; Lopez-Bresnahan MV
    Adv Ther; 2011 Sep; 28(9):761-75. PubMed ID: 21870169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.
    Miravalle A; Jensen R; Kinkel RP
    Arch Neurol; 2011 Feb; 68(2):186-91. PubMed ID: 20937940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment.
    Wickström A; Nyström J; Svenningsson A
    Mult Scler; 2013 Apr; 19(5):622-30. PubMed ID: 23012254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.